OGT launched a SureSeq Myeloid MRD Plus NGS panel engineered to detect measurable residual disease (MRD) in AML down to allele fractions as low as 0.01%, coupled with Interpret bioinformatics for longitudinal MRD tracking. The panel targets 16 AML biomarkers including FLT3 and NPM1 and promises sensitive detection of complex variants like long FLT3‑ITDs. Complementing diagnostics advances, SPT Labtech partnered with Alithea Genomics to automate ultra‑sensitive single‑cell transcriptomics by integrating MERCURIUS FLASH‑seq chemistry with SPT’s firefly liquid‑handling platform. The automated workflow aims to scale single‑cell RNA‑seq with improved reproducibility and throughput, addressing a bottleneck in large‑scale translational and clinical studies. Clarification: MRD refers to tiny amounts of residual malignant cells after treatment; ultra‑sensitive MRD assays inform prognosis and guide therapy adjustments in hematologic malignancies.